Stock NUS NU SKIN ENTERPRISES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nu Skin Enterprises, Inc. Berne S.E.

Equities

NUS

US67018T1051

Delayed Berne S.E.
Other stock markets
 17:00:00 05/03/2024 GMT 		5-day change 1st Jan Change
11.35 CHF -.--% Intraday chart for Nu Skin Enterprises, Inc. -.--% -.--%
07-01 Nu Skin Enterprises, Inc.(NYSE:NUS) added to Russell 2000 Dynamic Index CI
05-09 DA Davidson Adjusts Nu Skin Enterprises' Price Target to $12.50 From $15.50, Keeps Neutral Rating MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • With a P/E ratio at 11.76 for the current year and 7.48 for next year, earnings multiples are highly attractive compared with competitors.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.41 for the 2024 fiscal year.
  • The company has a low valuation given the cash flows generated by its activity.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
NU SKIN ENTERPRISES, INC. Stock Nu Skin Enterprises, Inc.
-.--% 531M -
PROCTER & GAMBLE COMPANY Stock Procter & Gamble Company
+11.80% 387B
C-
UNILEVER PLC Stock Unilever PLC
+13.21% 136B
B-
COLGATE-PALMOLIVE COMPANY Stock Colgate-Palmolive Company
+20.30% 78.86B
A+
HINDUSTAN UNILEVER LIMITED Stock Hindustan Unilever Limited
-5.75% 69.96B
A-
ESTEE LAUDER Stock Estee Lauder
-27.22% 37.96B
B+
BEIERSDORF Stock Beiersdorf
+0.07% 32.83B
B-
ESSITY AB Stock Essity AB
+9.32% 18.11B
A-
GODREJ CONSUMER PRODUCTS LIMITED Stock Godrej Consumer Products Limited
+20.93% 16.8B
B
DABUR INDIA LIMITED Stock Dabur India Limited
+9.42% 12.8B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NUS Stock
  4. NUS Stock
  5. Ratings Nu Skin Enterprises, Inc.